Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZGR in SBLPN
NCT07165769Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib, obinutuzumab, lenalidomide in splenic B-cell lymphoma (SBL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Sep 2025; status: recruiting.
02
Drugs
zanubrutinibobinutuzumablenalidomide
03
Conditions
splenic B-cell lymphoma (SBL)
Beyond the preview
Go deeper on NCT07165769.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07165769.